Diffuse large B-cell lymphoma (DLBCL) is the most common non-Hodgkin lymphoma; it
features extreme molecular heterogeneity regardless of the classical cell-of-origin (COO) …

Nodular lymphocyte-predominant Hodgkin lymphoma (NLPHL) is a rare lymphoma of B-cell
origin with frequent expression of functional B-cell receptors (BCRs). Here we report that …

Nodular lymphocyte-predominant Hodgkin lymphoma (NLPHL) is a Hodgkin lymphoma
expressing functional B-cell receptors (BCR). Recently, we described a dual stimulation …

Real-world data (RWD) are essential to complement clinical trial (CT) data, but major
challenges remain, such as data quality. REal world dAta in LYmphoma and Survival in …

Six cycles of the anti-CD20 antibody rituximab (R) plus cyclophosphamide, doxorubicin,
vincristine, and prednisone (CHOP) or CHOP-like chemotherapy are recommended by the …

Patients with diffuse large B‐cell lymphoma (DLBCL) who fail to complete planned treatment
with R‐CHOP due to toxicity are sparsely described. We investigated the extent of failure to …

Objective To describe 4-year survival outcomes and assess the value of established and
additional relevant variables to predict complete response (CR), four-year progression-free …

Objective: To describe 4-year survival outcomes and assess the value of established and
additional relevant variables to predict complete response (CR), four-year progression-free …

Introduction: In the era of routine use of positron emission tomography/computed
tomography (PET/CT) for staging, it is not yet clear whether PET/CT can replace bone …

Four cycles of rituximab plus CHOP (cyclophosphamide, doxorubicin, vincristine, and
prednisone) chemotherapy is as effective as six cycles in low-risk diffuse large B-cell …